Results 1 to 10 of about 4,158 (170)
Recent progress in combination therapy of oncolytic vaccinia virus [PDF]
Frontiers in ImmunologyIn recent years, oncolytic viruses have emerged as promising agents for treating various cancers. An oncolytic virus is a non-pathogenic virus that, due to genetic manipulation, tends to replicate in and cause lysis of cancerous cells while leaving ...
Seyedeh Nasim Mirbahari +12 more
doaj +6 more sources
Research progress and development potential of oncolytic vaccinia virus [PDF]
Chinese Medical Journal. Oncolytic virotherapy is a promising therapeutic approach treating tumors, where oncolytic viruses (OVs) can selectively infect and lyse tumor cells through replication, while also triggering long-lasting anti-tumor immune responses. Vaccinia virus (VV)
Xinyu Zhang +4 more
doaj +4 more sources
Oncolytic vaccinia virus and cancer immunotherapy. [PDF]
Front Immunol, 2023 Oncolytic virotherapy (OVT) is a promising form of cancer treatment that uses genetically engineered viruses to replicate within cancer cells and trigger anti-tumor immune response. In addition to killing cancer cells, oncolytic viruses can also remodel the tumor microenvironment and stimulate a long-term anti-tumor immune response.
Xu L, Sun H, Lemoine NR, Xuan Y, Wang P.
europepmc +4 more sources
Oncolytic Vaccinia Virus in Lung Cancer Vaccines [PDF]
Vaccines, 2022 Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effective cancer immunotherapy and thus can also be ...
Cao-Sang Truong +2 more
exaly +4 more sources
Biomedicines, 2020 As a live biologic agent, oncolytic vaccinia virus has the ability to target and selectively amplify at tumor sites. We have previously reported that deletion of thymidine kinase and ribonucleotide reductase genes in vaccinia virus can increase the ...
Franck Gallardo +14 more
doaj +3 more sources
Molecular Therapy: Oncolytics, 2019 Oncolytic vaccinia viruses are currently in clinical development. However, the safety and the tumor selectivity of these oncolytic viruses must be improved.
Johann Foloppe +9 more
doaj +3 more sources
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. [PDF]
PLoS Medicine, 2007 Oncolytic viruses hold much promise for clinical treatment of many cancers, but a lack of systemic delivery and insufficient tumor cell killing have limited their usefulness.
David H Kirn +4 more
doaj +3 more sources
Molecular Therapy: Oncolytics, 2018 Despite the effectiveness of classic treatments and available diagnostic tools, cancer continues to be a leading world health problem, with devastating cancer-related death rates.
Ernesto Mejías-Pérez +2 more
doaj +3 more sources
Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12 [PDF]
Molecular Therapy: OncologyOncolytic viruses are engineered to selectively kill tumor cells and have demonstrated promising results in early-phase clinical trials. To further modulate the innate and adaptive immune system, we generated AZD4820, a vaccinia virus engineered to ...
Cheyne Kurokawa +21 more
doaj +2 more sources
Molecular Therapy: Oncolytics, 2021 Characterization of the intratumoral immune status is important for developing immunotherapies and evaluating their antitumor effectiveness. CD8+ T cells are one of the most important cell types that directly and indirectly contribute to antitumor ...
Midori Yamashita +5 more
doaj +3 more sources